Kazia Therapeutics announced two poster presentations at the 2026 San Antonio Breast Cancer Symposium showcasing new preclinical research on paxalisib. The studies highlight paxalisib's unique ability to reprogram tumor and immune biology differently from other PI3K/mTOR inhibitors and its potential to reduce recurrence and metastasis in triple-negative breast cancer. This supports a novel mechanism of action beyond typical kinase inhibition. Kazia continues to develop paxalisib for multiple cancers, including breast cancer, with ongoing research and regulatory designations supporting its clinical potential.
Kazia Therapeutics' research on paxalisib is the subject, with Pluang's Health sector market data as context. As of Nov 02, 2026 18:12 WIB, out of 150 priced Health-sector US stocks tradable on Pluang, 70 rose and 54 fell today. Notable movers include TWST at USD 157.77 with a +3.27% change and a typical hold time of 27 days.
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Tigo Energy, Fluence Energy, and Anavex Life Sciences. The lawsuits allege these companies made false or misleading stat...
Heineken N.V. has repurchased a total of 9,510,681 shares under the second tranche of its €1.5 billion share buyback program, spending €679.2 million as of October 30, 2026. The company bought 159,700 shares on the exchange and 160,530 shares from He...
Alvotech, a global biotech company specializing in biosimilars, announced its management team will participate in several investor conferences in November 2026, including events in London, Oslo, and Stockholm. These presentations and fireside chats w...
Alvotech, a global biotech company specializing in biosimilar medicines, announced its management team will participate in several investor conferences throughout November 2026. These include events in London, Oslo, and Stockholm, featuring presentat...
Alvotech, a global biotechnology company specializing in biosimilar medicines, will participate in four international investor conferences in November held in the UK, Norway, and Sweden. These events include presentations and analyst discussions host...
